Biography
Biography: Ken Mills
Abstract
The advancement of next generation sequencing has identified a spectrum of mutations that contribute to the different types of blood cancers. These mutations can be used for the diagnostic classification and monitoring but in acute myeloid leukemia (AML) and with the exception of acute promyelocytic leukemia (APL); have not resulted in the development of novel targeted therapies. In this keynote presentation, the author will explore the range of mutations and their interactions, examine some of the molecular consequences of these and potentially how the epigenetic therapies may be useful across the different sub-types.